Quercetin: New Hype for COVID-19?
Now open: Certificate Course in Management of Covid-19 by Govt. Of Gujarat and PlexusMDKnow more...Now open: Certificate Course in Management of Covid-19 by Govt. Of Gujarat and PlexusMDKnow more...
Get authentic, real-time news that helps you fight COVID-19 better.
Install PlexusMD App for doctors. It's free.
SARS-CoV-2 represents an emergent global threat which is straining worldwide healthcare capacity. It is imperative to study and develop pharmacological treatments suitable for the prevention and treatment of COVID-19.

A plant flavonoid found in capers and green tea is being eyed by some as a potential adjunct therapy for patients with COVID-19, but whether quercetin will stand the test of rigorous trials remains unclear.

Antiiviral, Antioxidant Mechanisms:

-- Quercetin has long been evaluated for its potential protective effects against cancers, heart disease, and cells that release histamines.
-- The agent promotes SIRT2, which then inhibits the NLRP3 inflammasome assembly involved with COVID-19 infection.
-- It also plays a role in facilitating zinc transportation across lipid membranes.

An open-label randomized control trial in Turkey examined quercetin's role in COVID-19. In the trial, 95 patients with COVID-19 are receiving a 1,000-mg active treatment dose and 113 healthcare workers are receiving a 500-mg dose as prophylaxis. In both treatment arms, quercetin is administered with vitamin C and bromelain, a supplement extracted from pineapples that is used for burns or inflammation.

As of March, no COVID-19 cases were recorded among healthcare workers taking prophylactic quercetin and no deaths were observed among patients with COVID-19 on quercetin treatment.

There is evidence that vitamin C and quercetin co-administration exerts a synergistic antiviral action due to overlapping antiviral and immunomodulatory properties and the capacity of ascorbate to recycle quercetin, increasing its efficacy.

The Next HCQ?

Researchers compared the recent attention quercetin is receiving to the early popularity of hydroxychloroquine, which showed promise in preclinical studies. Ultimately, hydroxychloroquine was shown to have no survival benefit and in fact trended toward an increased risk of death among COVID-19 patients.

Source: https://www.frontiersin.org/articles/10.3389/fimmu.2020.01451/full
Dr. T●●●●z H●●●●●●i and 6 others like this3 shares
G●●●l K●●●h
G●●●l K●●●h General Medicine
Jul 2, 2020Like
Dr. S●n B●n
Dr. S●n B●n Internal Medicine
Jul 2, 2020Like